Cerevel Therapeutics Holdings, Inc.
CEREDelisted Aug 1, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001805387
Cerevel Therapeutics Holdings, Inc. was delisted on Aug 1, 2024; its insiders filed their last Form 4 on Aug 5, 2024; 231 institutions reported holding it in 13F filings for Q2 2024, worth $6.42B in total; Soros Fund Management was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Cerevel Therapeutics Holdings, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Cerevel Therapeutics Holdings, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Bain Capital Investors LLC | Director, 10% Owner | 0Indirect | Aug 5, 2024 | 0 |
| Bain Capital Fund XII, LP | Director, 10% Owner | 0Indirect | Aug 5, 2024 | 0 |
| BCPE Perception GP, LLC | Director, 10% Owner | 0Indirect | Aug 5, 2024 | 0 |
| BC Perception Holdings, LP | Director, 10% Owner | 0Indirect | Aug 5, 2024 | 0 |
| Bain Capital Partners XII, LLC | Director, 10% Owner | 0Indirect | Aug 5, 2024 | 0 |
| Pfizer Inc | Other: Former 10% Owner | 0 | Aug 5, 2024 | 0 |
| Patrick Deval L | Director | 0 | Aug 5, 2024 | 0 |
| Riedel Norbert G | Director | 0 | Aug 5, 2024 | 0 |
| Coles N Anthony | Director | 0 | Aug 5, 2024 | 0 |
| Dekkers Marijn E | Director | 0Indirect | Aug 5, 2024 | 0 |
| Sulzberger Gabrielle | Director | 0 | Aug 5, 2024 | 0 |
| Renaud Ronald C JR | President & CEO | 0Indirect | Aug 5, 2024 | 0 |
| Giordano Douglas E. | Director | 0 | Aug 5, 2024 | 0 |
| Gordon Christopher R | Director, 10% Owner | 0Indirect | Aug 5, 2024 | 0 |
| Mckernan Ruth | Director | 0 | Aug 5, 2024 | 0 |
| DiPietro Kenneth | Chief Human Resources Officer | 0 | Aug 5, 2024 | 0 |
| Koppel Adam | Director, 10% Owner | 0Indirect | Aug 5, 2024 | 0 |
| Burgess Paul D. | See Remarks | 0 | Aug 5, 2024 | 0 |
| Akamine Scott | Chief Legal Officer | 0 | Aug 5, 2024 | 0 |
| ALTSCHULLER Susan | Chief Financial Officer | 0 | Aug 5, 2024 | 0 |
| Sanchez Ramiro | Chief Medical Officer | 0 | Aug 5, 2024 | 0 |
| Renger John | Chief Scientific Officer | 0 | Aug 5, 2024 | 0 |
| Bodenrader Mark | See Remarks | 0 | Aug 5, 2024 | 0 |
| Tregoning Kathleen | See Remarks | 0 | Aug 5, 2024 | 0 |
| Edelman Joseph | Director | 0Indirect | Feb 21, 2024 | 0 |
| Perceptive Advisors LLC | Director | 0Indirect | Feb 21, 2024 | 0 |
| Perceptive Life Sciences Master Fund Ltd | Director | 0Indirect | Feb 21, 2024 | 0 |
| Ceesay Abraham | President | 0 | Feb 8, 2023 | 0 |
| PF Equity Holdings 1 B.V. | 10% Owner | 0 | Apr 4, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 19, 2023 (view filing) | Dec 15 | 4 days | Sanchez RamiroChief Medical Officer | SSale | −7.50K | $41.39 | −$310.4K | −100.0%0 after | |
| Dec 21, 2023 (view filing) | Dec 20 | 1 day | Tregoning KathleenSee Remarks | SSale | −6.29K | $41.42 | −$260.4K | −45.6%7.52K after | |
| Dec 21, 2023 (view filing) | Dec 20 | 1 day | ALTSCHULLER SusanChief Financial Officer | SSale | −13.8K | $41.42 | −$571.9K | −44.9%16.9K after | |
| Dec 21, 2023 (view filing) | Dec 20 | 1 day | Sanchez RamiroChief Medical Officer | SSale | −10.2K | $41.42 | −$420.5K | −40.9%14.7K after | |
| Dec 21, 2023 (view filing) | Dec 20 | 1 day | Akamine ScottChief Legal Officer | SSale | −7.07K | $41.42 | −$292.9K | −49.4%7.24K after | |
| Dec 21, 2023 (view filing) | Dec 20 | 1 day | DiPietro KennethChief Human Resources Officer | SSale | −6.26K | $41.42 | −$259.1K | −20.2%24.7K after | |
| Dec 21, 2023 (view filing) | Dec 20 | 1 day | Bodenrader MarkSee Remarks | SSale | −7.89K | $41.42 | −$326.8K | −30.8%17.7K after | |
| Dec 27, 2023 (view filing) | Dec 22 | 5 days | DiPietro KennethChief Human Resources Officer | SSale | −8.00K | $41.45 | −$331.6K | −24.5%24.7K after | |
| Dec 28, 2023 (view filing) | Dec 26 | 2 days | Sanchez RamiroChief Medical Officer | SSale | −10.0K | $42.47 | −$424.7K | −40.5%14.7K after | 10b5-1 |
| Jan 4, 2024 (view filing) | Jan 2 | 2 days | Coles N AnthonyDirector | SSale | −50.0K | $42.24 | −$2.11M | −94.9%2.70K after | 10b5-1 |
| Feb 8, 2024 (view filing) | Feb 7 | 1 day | Coles N AnthonyDirector | SSale | −2.51K | $41.54 | −$104.1K | −13.8%15.6K after | |
| Feb 8, 2024 (view filing) | Feb 7 | 1 day | Renger JohnChief Scientific Officer | SSale | −2.16K | $41.54 | −$89.8K | −25.3%6.37K after | |
| Mar 4, 2024 (view filing) | Feb 29 | 4 days | Coles N AnthonyDirector | SSale | −50.0K | $41.16 | −$2.06M | −76.2%15.6K after | 10b5-1 |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Coles N AnthonyDirector | SSale | −50.0K | $41.01 | −$2.05M | −76.2%15.6K after | 10b5-1 |
| Apr 3, 2024 (view filing) | Apr 1 | 2 days | Coles N AnthonyDirector | SSale | −50.0K | $42.33 | −$2.12M | −76.2%15.6K after | 10b5-1 |
| May 14, 2024 (view filing) | May 10 | 4 days | Coles N AnthonyDirector | SSale | −50.0K | $42.10 | −$2.10M | −76.2%15.6K after | 10b5-1 |
| Jun 5, 2024 (view filing) | Jun 3 | 2 days | Coles N AnthonyDirector | SSale | −50.0K | $40.61 | −$2.03M | −76.2%15.6K after | 10b5-1 |
| Jul 3, 2024 (view filing) | Jul 1 | 2 days | Coles N AnthonyDirector | SSale | −25.0K | $41.18 | −$1.03M | −49.1%25.9K after | 10b5-1 |